Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368049 | 0.98 | CYP1A2 (0.44) | CYP1A2CYP2C19SMN1; SMN2HIF1AKDM4E | |
| SCHEMBL20715968 | 0.93 | CYP1A2 (0.41) | CYP1A2CYP2C19SMN1; SMN2HIF1AKDM4E | |
| SCHEMBL25633562 | 0.93 | BCL2 (0.46) | CYP1A2CYP2C19SMN1; SMN2HIF1AKDM4E | |
| SCHEMBL20715653 | 0.89 | TRPA1 (0.45) | CYP1A2CYP2C19SMN1; SMN2HIF1AKDM4E | |
| SCHEMBL20715965 | 0.89 | ALDH1A1 (0.41) | CYP1A2CYP2C19SMN1; SMN2HIF1AKDM4E | |
| SCHEMBL692554 | 0.89 | CTBP2 (0.49) | KDM4EPOLBALDH1A1CYP3A4HPGD | |
| SCHEMBL14611102 | 0.88 | ALDH1A1 (0.46) | CYP1A2CYP2C19ALDH1A1MEN1GAA | |
| SCHEMBL19776008 | 0.88 | PPARA (0.43) | CYP1A2CYP2C19SMN1; SMN2KDM4EPOLB | |
| SCHEMBL23123860 | 0.87 | RIPK1 (0.52) | EGFRL3MBTL1RIPK1TAAR1 | |
| SCHEMBL21313898 | 0.87 | RIPK1 (0.52) | SMN1; SMN2ALDH1A1HPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025096300-A1 | NOVEL METHODS FOR THE PREPARATION OF 3-AZABICYLCO[3.1,0]HEXANE-6-CARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2025-05-08 | — | — | WO | claimed |
| EP-3805337-B1 | INK COMPOSITIONS AND QUANTUM DOT POLYMER COMPOSITE PATTERN PREPARED FROM THE SAME | SAMSUNG DISPLAY CO LTD (KR) | 2023-08-09 | — | — | EP | claimed |
| US-11248139-B2 | Ink compositions and quantum dot polymer composite pattern prepared from the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2022-02-15 | — | — | US | claimed |
| EP-3805337-A1 | INK COMPOSITIONS AND QUANTUM DOT POLYMER COMPOSITE PATTERN PREPARED FROM THE SAME | Samsung Display Co., Ltd. (KR) | 2021-04-14 | — | — | EP | claimed |
| US-20210102084-A1 | INK COMPOSITIONS AND QUANTUM DOT POLYMER COMPOSITE PATTERN PREPARED FROM THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2021-04-08 | — | — | US | claimed |
| US-9783512-B2 | Bicyclic methylene aziridines and reactions thereof | WISCONSIN ALUMI RESEARCH FOUNDATION (US) | 2017-10-10 | — | — | US | claimed |
| US-20160075668-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2016-03-17 | — | — | US | claimed |
| US-9221842-B2 | Bicyclic methylene aziridines and reactions thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-12-29 | — | — | US | claimed |
| US-20130079511-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-03-28 | — | — | US | claimed |
| EP-4719393-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4635570-A2 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | Denali Therapeutics Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12358896-B2 | LRRK2 inhibitors and methods of making and using thereof | DENALI THERAPEUTICS INC. (US) | 2025-07-15 | — | — | US | disclosed |
| WO-2025096300-A1 | NOVEL METHODS FOR THE PREPARATION OF 3-AZABICYLCO[3.1,0]HEXANE-6-CARBOXAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-3998261-B1 | PYRIMIDIN-2-YLAMINO-1H-PYRAZOLS AS LRRK2 INHIBITORS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DENALI THERAPEUTICS INC (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20160340305-A1 | DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-24 | — | — | US | disclosed |
| US-20160075668-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2016-03-17 | — | — | US | disclosed |
| US-9221842-B2 | Bicyclic methylene aziridines and reactions thereof | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| WO-2015103505-A2 | DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS | ESS DANIEL HALSELL (US) | 2015-07-09 | — | — | WO | disclosed |
| US-20130079511-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-03-28 | — | — | US | disclosed |
| WO-2013033245-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340305-A1 | DIRECT STEREOSPECIFIC SYNTHESIS OF UNPROTECTED AZIRIDINES FROM OLEFINS | AAAS, NISCH, HNMT | CYP1A2 38/4885CYP2C19 93/4885SMN1; SMN2 3621/4885 |
| US-20160075668-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | AAAS, CYCS, AOC2 | CYP1A2 59/4885CYP2C19 39/4885SMN1; SMN2 3154/4885 |
| US-12358896-B2 | LRRK2 inhibitors and methods of making and using thereof | LRRK2, PARK7, GSK3B | CYP1A2 4568/4885CYP2C19 3095/4885SMN1; SMN2 174/4885 |
| US-20130079511-A1 | BICYCLIC METHYLENE AZIRIDINES AND REACTIONS THEREOF | AAAS, CYCS, AOC2 | CYP1A2 59/4885CYP2C19 39/4885SMN1; SMN2 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.